Attention-deficit hyperactivity disorder (ADHD) is the most common neurobiological disorder in children. Efficacy of pharmacotherapy in treating ADHD symptoms has generally been considerable with at least three-fourths of individuals benefiting from pharmacotherapy, typically in the form of stimulants. In this review, we begin by briefly reviewing the history of pharmacotherapy in relation to ADHD, before focusing (primarily) on the state of the field on themes such as biophysiology, pharmacokinetics, and pharmacogenomics. We conclude with a summary of emerging clinical and research studies, particularly the potential role for precision therapy in matching ADHD patients and drug types.
Background
Attention-deficit hyperactivity disorder (ADHD) is the most common neurobiological disorder in children, with a prevalence of approximately 6% to 7% 1,2 that has remained stable for decades. 2 The social and economic burden associated with patients, 3 families, and broader systems (health care/educational) is substantial, with the annual economic impact of ADHD exceeding US$30 billion in the US alone. 4 Efficacy of pharmacotherapy in treating ADHD symptoms has generally been considerable, with at least three-fourths of individuals benefiting from pharmacotherapy, typically in the form of stimulants. 5 In this review, we begin by briefly reviewing the history of pharmacotherapy in relation to ADHD, before focusing (primarily) on the state of the field on themes such as biophysiology, pharmacokinetics, and pharmacogenomics. We conclude with a summary of emerging clinical and research studies, particularly the potential role for precision therapy in matching ADHD patients and drug types.
Past
The most common and effective medications are methylphenidates and amphetamines. Atomoxetine and the a-adrenergic agonists are also widely used, while tricyclics such as modafinil and Wellbutrin are less common and typically less effective. 6 First synthesized in 1887, amphetamine (alpha-methylphenethylamine) was not studied clinically until 1927, initially as an artificial replacement for ephedrine. 7 For several years, it was developed primarily as a bronchodilator, though recognition of stimulant properties subsequently led to a broadening of clinical scope across several dozen conditions. 7 In 1937, the effects of benzedrine sulfate treatment were first documented in 30 children (21 boys, 9 girls; 5-14 years old) with a range of behavior disorders. The amphetamine was administered as a treatment for post-lumbar puncture headache, but consequent behavioral changes were marked, including a ''drive'' to accomplish as much as possible and improvement from a social viewpoint. 8 A larger follow-up study (N ¼ 100) in 1941 9 was less sweeping in its conclusions, but nevertheless documented ''subdued'' social impairment in 54% of the children studied. 10 By this point, amphetamines had been proposed as a treatment for a range of conditions, including schizophrenia, addiction, cerebral palsy, low blood pressure, and seasickness, 7 with less focus on ADHD. 10 It was not until the 1950s that research in stimulant drugs became truly relevant to ADHD (or precursors such as hyperkinetic disease, hyperkinetic impulse disorder, and minimal brain damage 11 ). By then, the amphetamine derivative methylphenidate had been synthesized (1944), 6, 12 and subsequently marketed as Ritalin. 11, 13 These developments coincided with the waning influence of psychoanalysis, and the belief that behavioral disorders had little or no biological basis. 11 In 1957, an important study addressing hyperkinetic impulse disorder in children's behavior problems defined hyperactivity as a potentially biological phenomenon, as well as delineating a role for stimulant drugs in its treatment. A surge of studies followed that cataloged the treatment of hyperactive children with stimulant medication, which was maintained as a therapy for the newly defined hyperkinetic reaction of childhood (DSM-II, 1968 14 ) and attention-deficit disorder (DSM III, 1980 15 ).
Currently, stimulant medication is the most common treatment for ADHD, where a diverse catalog of delivery mechanisms has facilitated the development of longer-acting compound preparations. Alternative drug treatments include norepinephrine reuptake inhibitor and a-adrenergic agonists.
Present
While the literature is consistent in confirming the effectiveness of pharmacotherapy in treating ADHD, it is notable that mechanisms of action (MOAs) are generally poorly understood and underdeveloped. Numerous studies have reported differential effects for ADHD medications in terms of associated neurobiology and relevant neurotransmitter systems. Simulants in particular have reportedly affected a plethora of brain regions, 16 neurotransmitters, 17 and gene regulators. 18, 19 Atomoxetine and the a-agonists have more targeted effects, and this may be reflected in the lower response rates. Table 1 , adapted from Elia et al, 6 summarizes approved medications worldwide including methylphenidate, amphetamines, a-adrenergic agonists, and a selective norepinephrine reuptake inhibitor. The most effective pharmacotherapies remain methylphenidate and amphetamine compounds.
Effectiveness and Effect Size
Relative to other psychiatric diseases, ADHD can be considered a poster child in terms of the effectiveness of drug treatments. Indeed, a large-scale meta-analysis by Leucht 6 ) summarizes the effect size of relevant ADHD treatments. In addition to stimulants, atomoxetine and a-adrenergic agonists are also effective in managing ADHD symptoms, however, as outlined, relevant effect sizes are comparably smaller to those of stimulants, a caveat being that often patients prescribed atomoxetine/a-adrenergic agonists may already have failed to respond to stimulants, so may not be a strictly representative cohort. Beyond ADHD core symptoms, pharmacotherapy has been associated with improved quality of life 26 and decreased risk of developing depression 27, 28 and anxiety/disruptive disorders over a 10-year period, 28 paralleled by improved grade retention. 28 A 2012 study of 25,656 ADHD patients from the Swedish national register compared criminal convictions across a 3-year period and found a significant decrease in the rate of criminality while patients were on ADHD medication versus the same patients unmedicated. 29 
Neurobiological Correlates
The mechanisms by which those medications listed in Table 1 impact on ADHD symptoms are poorly understood. Several studies report a role for methylphenidate in inhibiting dopamine transporters in the cortex and striatum. 30, 31 The same drug may also inhibit the norepinephrine transporter in the cortex. 31 The MOA may relate to amphetamine stimulating leakage of dopamine and norepinephrine into the synaptic cleft. In turn, this may inhibit their degradation and inactivate the storage protein pump. Ultimately, this would increase the extracellular availability of both neurotransmitters and also extracellular serotonin. Note (dosing/discontinuation): Dosing is typically (but not universally 79 ) weight based. With stimulants, optimal dosing is achieved by starting at the lowest dose and titrating based on efficacy/tolerability. The same is true for guanfacine and clonidine. With atomoxetine, weight helps establish a maximum dose of 1.2-1.4 mg/ kg/d. Discontinuing stimulants and lower doses of atomoxetine does not require tapering. However, to prevent rebound and increased blood pressure, tapering is recommended for a-agonists. 
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Stimulants
Improvements in attention associated with taking methylphenidate are correlated with increased dopamine levels in the ventral striatum, prefrontal cortex (PFC), and temporal cortex. 33 Methylphenidate administration has also been associated with normalizing underactive frontocingulate networks 34 and striatal areas 35 and increased frontoparietal connectivity for working memory. 36 Other neurobiological changes observed in relation to methylphenidate administration include enhanced error detection associated with the dorsal anterior cingulate cortex and inferior parietal lobe, 37 and optimized speed of reaction related to (pre-)motor cortex. 38 A number of other gross neurobiological effects have been associated with taking methylphenidate, including increased activation in the caudate, cerebellum, midbrain, substantia nigra, thalamus, 39 and many others. Wong et al 36 report increased functional connectivity in the anterior cingulate, ventrolateral PFC, and precuneus, which is also associated with working memory. Atomoxetine increases the availability of norepinephrine (noradrenaline) and dopamine in the PFC, 40 selectively inhibiting relevant transporters presynaptically. It is also an NMDA receptor antagonist, thereby altering glutamatergic transmission. 41 Unlike stimulants, atomoxetine is not strongly associated with striatal effects and is less likely to be abused (full effect also takes 4-6 weeks). Neurobiological correlates of atomoxetine administration include increased regional cerebral blood flow in the cerebellar cortex, and decreased blood flow to the midbrain, substantia nigra, and thalamus. 39 Enhanced inhibitory control following atomoxetine has also been associated with increased activation of the right inferior frontal gyrus. 42 a-Adrenergic agonists Guanfacine inhibits cyclic AMP, closing hyperpolarizationactivated (HCN) cyclic nucleotide-gated channels and increasing functional connectivity in the PFC. By blocking or knocking-down HCN1 channels in the PFC, guanfacine can improve working memory. 43 Guanfacine has been shown to increase activation in the dorsolateral PFC. It is noteworthy that glutamatergic synapses have heteroceptors that are inhibitory a2A-adrenoceptors, 44 and it is possible (though admittedly speculative) that clonidine and guanfacine are effective by reducing presynaptic glutamate release in the PFC. This hypothesis is supported by a recent study by Miller et al, 45 which showed abnormal glutamate signaling in the signaling in PFC and striatum of the spontaneously hypertensive rat model of ADHD. The potential role for glutamatergic medication in treating ADHD is discussed further below.
Safety
As illustrated in Table 3 , ADHD medications have been associated with a range of common and rare adverse effects 46 that correlate with age/developmental stage. 22 While many adverse events are often transient and dose dependent, 47 effects such as appetite loss may persist for years. 48 Adverse events may also be genotype-specific, with, for example, CYP2D6 poor metabolizers at greater risk with atomoxetine. 49 As outlined, cardiovascular effects are among the most serious adverse events. Sudden death, reported in 4 children taking clonidine, are particularly concerning, but investigations into these deaths attribute likely cause to preexisting cardiac conditions and concomitant drug treatment. 6 Bradycardia, however, has been consistently reported with clonidine-in up to 17.5% of patients on mono-or combined therapy with stimulants, versus 3.4% in nonusers. 50 The same study also found drowsiness with acute hepatitis following atomoxetine. In one, no competing diagnosis was found, and liver injury resolved by discontinuing atomoxetine. In the second, evaluation suggested type 1 autoimmune hepatitis, which also ameliorated with discontinuation and concomitant immunosuppressive therapy. Self-injury/ideation is another adverse event on the more serious spectrum. Such ideation has been reported in *1.5% of patients prescribed atomoxetine or stimulants, and monitoring for such effects is warranted. Additional limitations include generally short half-lives that diminish behavioral efficacy to several hours/day for the stimulants and drug interactions via P450-2D6 for atomoxetine.
Pharmacogenomics (PGx)
Several reviews have cataloged the role of genetic variants in mediating responses to ADHD medication, indicating mixed and inconclusive results, 54, 55 and suggesting that, similar to the disease itself, drug response is a highly complex trait. Indeed, methylphenidate has been reported (in rats) to upregulate expression of >700 genes in the striatum involved in neural/synaptic plasticity, including neurotransmitter receptors, proteins responsible for transport and anchoring, and many others. 56 Thus, a reason why stimulants show efficacy in most individuals may be due to the fact that they affect expression in numerous genes throughout the brain, thus impacting on potentially numerous variants. For similar reasons, response rates may be lower for the more selective medications such as atomoxetine and a-adrenergic agonists, potentially with fewer variants involved. The majority of PGx-based studies have focused on existing ADHD medications, primarily methylphenidate, with the goal of identifying specific biomarkers of drug response, which are reviewed briefly here (see also Bruxel et al 57 ) . One exception to this approach is a study from our group, which has used results from genomics analyses to identify novel drug targets for a genome-stratified ADHD subcohort.
Dopaminergic system
Interactions between DAT1 genotypes and methylphenidate response are among the most widely studied in terms of ADHD and PGx. The dopamine active transporter (DAT) protein encoded by DAT1 is widely expressed in the dopaminergic system, particularly in projections to the nucleus accumbens and striatum. 58 Several variable number tandem repeats (VNTRs) have been identified for DAT1, with the 9-repeat and 10-repeat alleles. Froehlich et al 59 57 ), but as yet none constitute a stand-out model for targeted/precision intervention. Below, we discuss a different approach to the PGx model, in which genomics results can be used to guide development of novel therapeutics (as opposed to stratify response to existing medications).
Future
A recent study sequenced 202 genes (including dopaminergic, adrenergic, glutamatergic, histaminergic, and cholinergic receptor genes-considered potential drug targets) in approximately 14,000 individuals (not ADHD) and discovered that 95% of genetic variants were not common but rare (occurring in less than 0.5% of the population), with 74% found in only 1 or 2 individuals. 64 This further suggests that-not only for ADHD but for other disorders as well-pharmacotherapeutic targets of the future are likely to focus on rarer genetic variants.
To this end, a large-scale, genomewide study from our group compared copy number variations (CNVs) in ADHD cases (3,500) versus controls (*13,000) revealed that rare, recurring CNVs impacting specific GRM genes (ie, GRM1, GRM5, GRM7, and GRM8) encoding for metabotropic glutamate receptors (mGluRs) were found in ADHD patients at significantly higher frequencies compared to healthy controls. 65 The large effect sizes (with odds ratios of >15) suggest that these mutations likely are highly penetrant for their effects on ADHD. Single cases with GRM2 and GRM6 deletions were also observed that were not found in controls.
When genes in the signaling pathway of GRM genes (ie, a GRM/mGluR network) were assessed, significant enrichment of CNVs was found to reside within this network in ADHD cases compared to controls. Our group recently identified 228 genes within the GRM gene networks based on the merged human interactome provided by the Cytoscape Software. 18 A network analysis of the mGluR pathway found that in the EA population of approximately 1,000 cases and 4,000 controls, genes involved with GRM signaling or their interactions are significantly enriched for CNVs in cases (P ¼ 4.38 Â 10 -10
), collectively impacting *12% of the ADHD cases, corrected for control occurrence ( Figure 1B ). These data suggest that GRMs may serve as critical hubs that coordinate highly connected modules of interacting genes, many of which harbor CNVs and are enriched for synaptic and neuronal biological functions. Thus, we have identified several rare recurrent CNVs that are overrepresented in multiple independent ADHD cohorts that impact genes involved in glutamatergic neurotransmission, which is essential for the developing brain and normal brain function. These results suggest that variations involving mGluR gene networks contribute to the genetic susceptibility of ADHD. Further, disrupted mGluR signaling/ activity in ADHD in a subcohort can be identified based on genetic profiling of their genes within this GRM network and selectively drug targeted.
Discovering efficacious novel therapeutics for neuropsychiatric disorders has proven to be difficult in part because of the lack of a clear understanding of their molecular etiologies. 66 Our group's research in ADHD is focused on characterizing genetic variants that disrupt a specific pathway (the glutamatergic pathway) involving neurotransmission in the brain. We recently identified a small molecule compound, NFC-1, which previously underwent extensive clinical testing 67 and was shown to have stimulatory activity towards mGluR pathways, [68] [69] [70] producing notable psychoactive effects in animal models. 71, 72 The drug was originally developed in the late 1980s for treating dementia-related cognitive impairment but was eventually abandoned during phase III trials in dementia. The drug was shown to be safe and well tolerated. Studies in primates and rodents also demonstrated no signs of addiction or dependency to the drug. 
Clinical Trial in mGluR Biomarker-Positive Patients With ADHD
Through a comprehensive survey of published studies and public databases, we identified drug candidates that act on the mGluR pathway and could potentially rescue the underlying neurogenetic defects in patients with the ADHD. As discussed, our network analysis directly implicates the known action of NFC-1 as a potential pharmacological agent that may be efficacious in patients with ADHD because of highly penetrant genetic defects in the mGluR pathway. NFC-1 is not currently approved for any indication; however, it is known to exhibit nootropic effects and have cognition-enhancing properties. Its safety profile has been well established, having undergone phase I, II, and III clinical trials for other indications. NFC-1 is a member of the piracetam-like drug family, and the published literature on the piracetam-like drug confirms that these compounds in clinical use are well tolerated, generally safe, and effective for their respective indications. [74] [75] [76] Moreover, this class of compounds has also been used in studies involving children. 76, 77 NFC-1, which exhibits stimulatory activity for all 3 groups of mGluRs, has been shown to improve cognitive functions in animal models. Thus, NFC-1 presents an important candidate to explore for use in restoring mGluR activity in those ADHD patients exhibiting rare mGluR gene network mutations. Based on NFC-1's safety/tolerability profile, it is highly unlikely that it will possess the risks and side effects associated with conventional ADHD medications. Also, a pharmacogenomics approach, where efficacy of NFC-1 is assessed in relation to the patients' genomic profile, will determine whether responders can be segregated from nonresponders, which would be a major improvement compared to current . 6 Color available in the online version of this article.
nonstimulant, targeted therapies (atomoxetine, guanfacine) for which responders cannot be prospectively identified. NFC-1 previously entered phase III clinical trial in adult dementia patients with cerebrovascular diseases, but the program was suspended when the drug did not reach the defined efficacy endpoints, although safety expectations were met.
Pharmacokinetics in Elderly Versus Young Adults
Pharmacokinetic studies of NFC-1 in elderly and young subjects have been published. 78 Fourteen healthy male volunteers (7 elderly subjects aged 68-79 years and 7 young subjects aged 20-32 years) were included in the study (Table 4) . In a parallel group design, a tablet containing 100 mg NFC-1 was administered orally after breakfast. The maximum plasma concentration (C max ) was higher in the elderly (mean + SD ¼ 3.06 + 0.69 mg/mL [elderly] vs 2.13 + 0.34 mg/mL [young]; P ¼ .0117), and the area under the plasma concentration curve (AUC) was also higher in the elderly (24.6 + 4.4 mgÁh/mL vs 14.4 + 3.1 mgÁh/mL; P ¼ .0006). A significant correlation was found between renal clearance of NFC-1 and creatinine clearance of each subject (r ¼ 0.583, P ¼ .0364). These observations indicate that the plasma concentration of NFC-1 will increase in elderly subjects mainly due to a decrement in renal clearance of the drug. We will complete the first clinical trial in adolescents aged 12 to 17 years, using 4 active doses (50, 100, 200 , and 400 mg twice daily) as well as placebo. The results from the study will be made available later this year. We believe this approach is indicative of a new model to ADHD precision medicine, in which genomics are used to propose novel drugs for targeted treatment.
Conclusion
It is clear that traditional drug treatments for ADHD have been largely effective, but considerable work remains to be done to elucidate methods of action. Genomics are beginning to play a larger role in such efforts, and technological advances in the past decade have accelerated identification of candidate variants associated with ADHD susceptibility. In particular, these approaches can rapidly feed-forward to translational pipelines, offering further opportunities to target treatments to genomically-characterized cohorts. One recent approach has been to target individuals with specific variants in glutamatergic pathways, with a clinical trial now ongoing. Accelerating cost reductions and higher outputs of genotyping/sequencing approaches makes the identification and eventual targeting of these and potentially other transmitter systems (eg, dopaminergic/noradrenergic) a real possibility, offering cause for optimism as we navigate the precision medicine era.
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